DSCSA Support: The Benefits of Leveraging EPCIS

The pharma industry is exploring the use of the Electronic Product Code Information Service to help meet the immediate and long-term requirements of the Drug Supply Chain Security Act

By Peter Sturtevant, senior director of industry engagement, GS1 US

With the next two compliance dates for the Drug Supply Chain Security Act (DSCSA) approaching, pharma industry professionals need to make important decisions related to serialization and the exchange of transaction level data. Through the GS1 Healthcare US industry initiative, the pharmaceutical industry is exploring the use of the global GS1 and ISO standard called the Electronic Product Code Information Services (EPCIS) to help meet both the immediate and long-term requirements of DSCSA.

EPCIS has been supported by the Food and Drug Administration as a communication method for reporting transactional information and provides the data attributes and message structure needed to comply with the information handling and retrieval provisions of the DSCSA. Still, some companies are unaware of this standard’s many benefits. Let’s explore EPCIS and why and how it can be implemented to address regulatory requirements:

1. EPCIS works with standards many pharma companies are already using.
EPCIS works within the GS1 System of Standards, which is likely to already be a part of the industry’s existing product identification and information sharing processes. GS1 identifiers like Global Trade Item Numbers (GTINs) and Global Location Numbers (GLNs) play a foundational role in uniquely identifying a product and the place it was manufactured. GTINs specifically describe products and GLNs provide unique location information for each product in the pharma supply chain. They are essentially the pieces of information about pharmaceuticals, logistics units and other assets in the supply chain that flow between trading partners via EPCIS.

2. EPCIS is versatile.
With its extreme scalability and versatility, EPCIS allows for healthcare industry-specific enhancements to be implemented using a number of GS1 barcodes and data carriers. EPCIS also allows companies to share master data imbedded in the event or document, or through a query mechanism. In addition, EPCIS is the only global standard. Leveraging standards to meet specific geographic or market needs helps trading partners to achieve regulatory compliance and improve global supply chain efficiency.

3. Successful pilot programs are being reported.
There are many trading partner pilots underway this year that leverage EPCIS according to industry recommendations for adoption. Recently, an industry solution provider announced the completion of a successful EPCIS pilot program conducted with a top pharmaceutical manufacturer and top wholesale distributor. The pilot program was designed to test real-world scenarios, managing the preparation, exchange and verification of serialized product information in a production environment for commercial product. They reported high operational speed and maintenance of a high level of efficiency in the processing of thousands of serialized units.

Since late 2014, the industry has been leveraging the GS1 US guideline “Applying GS1 Standards to U.S. Pharmaceutical Supply Chain Business Processes to Support the Drug Supply Chain Security Act.” This guidance was developed in collaboration with more than 160 GS1 Healthcare US initiative members prior to the first DSCSA deadline. An updated version is expected to be published later this year.

4. EPCIS helps a company collaborate long term with different supply chain partners.
It is beneficial to think of EPCIS adoption beyond simply meeting the compliance date, as the ROI is significant over the long term as well. According to a recent Acsis survey, researchers cautioned manufacturers taking a “compliance now” approach that they may get caught with long-term costs and rework of initiatives to build a truly traceable warehouse. In general, the implementation of standards, including EPCIS, can protect brands from risk in a variety of ways, such as providing improved recall readiness, and the ability to document chain of custody, minimizing opportunities for counterfeit drugs to circulate through the supply chain. By failing to recognize the long-term implications, companies can risk lowering productivity by adding additional manual processes.

Ultimately, with lot-level management compliance already underway, now is the time for healthcare organizations to update business processes and information systems in order to move the pharmaceutical industry forward into the next chapter of efficiency and growth. Through collaborative processes such as EPCIS adoption, manufacturers and other industry stakeholders can continue their transition to a safer, automated and serialized supply chain.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments